DK351887D0 - Kombinationsdosisform til hormonbehandling og kontraception for kvinder i praemenopausen - Google Patents

Kombinationsdosisform til hormonbehandling og kontraception for kvinder i praemenopausen

Info

Publication number: DK351887D0
Authority: DK; Denmark
Prior art keywords: days; dosage form; combination; combination dosage; estradiol
Prior art date: 1986-07-15

Application number

DK351887A

Other languages

English (en)

Other versions

DK351887A (da

DK174724B1 (da

Inventor

Gertrude Virginia Upton

Original Assignee

American Home Prod

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-07-15

Filing date

1987-07-08

Publication date

1987-07-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25388101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK351887(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1987-07-08 Application filed by American Home Prod filed Critical American Home Prod

1987-07-08 Publication of DK351887D0 publication Critical patent/DK351887D0/da

1988-01-16 Publication of DK351887A publication Critical patent/DK351887A/da

2003-10-06 Application granted granted Critical

2003-10-06 Publication of DK174724B1 publication Critical patent/DK174724B1/da

Links

230000008602 contraction Effects 0.000 title 1
229940088597 hormone Drugs 0.000 title 1
239000005556 hormone Substances 0.000 title 1
239000002552 dosage form Substances 0.000 abstract 5
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 4
230000027758 ovulation cycle Effects 0.000 abstract 3
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 abstract 2
229960005309 estradiol Drugs 0.000 abstract 2
229960004400 levonorgestrel Drugs 0.000 abstract 2
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 abstract 1
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 abstract 1
229960004976 desogestrel Drugs 0.000 abstract 1
RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 abstract 1
239000000262 estrogen Substances 0.000 abstract 1
229940011871 estrogen Drugs 0.000 abstract 1
229960002568 ethinylestradiol Drugs 0.000 abstract 1
GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 abstract 1
SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 abstract 1
229960005352 gestodene Drugs 0.000 abstract 1
230000003054 hormonal effect Effects 0.000 abstract 1
IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 abstract 1
229960001390 mestranol Drugs 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229940053934 norethindrone Drugs 0.000 abstract 1
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 abstract 1
239000006187 pill Substances 0.000 abstract 1
239000000583 progesterone congener Substances 0.000 abstract 1
238000009256 replacement therapy Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

DK198703518A 1986-07-15 1987-07-08 Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet DK174724B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US88597186A	1986-07-15	1986-07-15
US88597186		1986-07-15

Publications (3)

Publication Number	Publication Date
DK351887D0 true DK351887D0 (da)	1987-07-08
DK351887A DK351887A (da)	1988-01-16
DK174724B1 DK174724B1 (da)	2003-10-06

Family

ID=25388101

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK198703518A DK174724B1 (da)	1986-07-15	1987-07-08	Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet
DK365887A DK365887D0 (da)	1986-07-15	1987-07-14	Kombinationsdoseringsform til hormonbehandling af kvinder i prae-menopausen

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK365887A DK365887D0 (da)	1986-07-15	1987-07-14	Kombinationsdoseringsform til hormonbehandling af kvinder i prae-menopausen

Country Status (20)

Country	Link
EP (1)	EP0253607B2 (da)
JP (1)	JP2645510B2 (da)
KR (1)	KR960001371B1 (da)
AT (1)	ATE75401T1 (da)
AU (1)	AU597084B2 (da)
CY (1)	CY1725A (da)
DE (1)	DE3778599D1 (da)
DK (2)	DK174724B1 (da)
ES (1)	ES2033850T5 (da)
GB (1)	GB2192542B (da)
GR (1)	GR3004472T3 (da)
HK (1)	HK67393A (da)
IE (1)	IE61236B1 (da)
LU (1)	LU90634I2 (da)
NL (1)	NL300025I2 (da)
PH (1)	PH25944A (da)
PT (1)	PT85305B (da)
SG (1)	SG55093G (da)
WO (1)	WO1988000469A1 (da)
ZA (1)	ZA875010B (da)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816258A (en) *	1987-02-26	1989-03-28	Alza Corporation	Transdermal contraceptive formulations
CH674618A5 (da) *	1987-04-02	1990-06-29	Ciba Geigy Ag
ATE66149T1 (de) *	1987-07-06	1991-08-15	Akzo Nv	Pharmazeutische dosierungseinheit zur vorbeugung bzw. behandlung von klimakterischen beschwerden.
FI101601B (fi) *	1987-09-24	1998-07-31	Jencap Res Ltd	Ehkäisyvalmiste sekä estrogeenin ja progestiinin käyttö ehkäisyvalmist een valmistusmenetelmässä
US5276022A (en) *	1987-09-24	1994-01-04	Jencap Research Ltd.	Hormone preparation and method
DE3916112A1 (de) *	1989-05-16	1990-11-22	Schering Ag	Dihydrospirorenon als antiandrogen
US5043331A (en) *	1989-06-15	1991-08-27	Orion-Yhtyma Oy	Treatment of postmenopausal disorders
IE71203B1 (en) *	1990-12-13	1997-02-12	Akzo Nv	Low estrogen oral contraceptives
IE62665B1 (en) *	1990-12-17	1995-02-22	Akzo Nv	Contraceptive regimen
MX9301121A (es) *	1992-03-02	1993-09-01	Schering Ag	Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
US7704983B1 (en)	1992-03-02	2010-04-27	Eastern Virginia Medical School	Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
DE59309063D1 (de) *	1992-03-21	1998-11-19	Entec	Verwendung von östriol zur herstellung einen transdermalen therapeutischen systeme zur behandlung von klimakterischer osteoporose
DE4227989A1 (de) *	1992-08-21	1994-06-09	Schering Ag	Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
US6407082B1 (en)	1996-09-13	2002-06-18	New Life Pharmaceuticals Inc.	Prevention of ovarian cancer by administration of a vitamin D compound
DE4344462C2 (de)	1993-12-22	1996-02-01	Schering Ag	Zusammensetzung für die Empfängnisverhütung
DE4411585A1 (de) *	1994-03-30	1995-10-05	Schering Ag	Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
US5552394A (en) *	1994-07-22	1996-09-03	The Medical College Of Hampton Roads	Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
US5922349A (en) *	1995-09-28	1999-07-13	Schering Aktiengesellschaft	Hormone replacement therapy method and hormone dispenser
US5747480A (en) *	1996-05-08	1998-05-05	American Home Products Corporation	Oral contraceptive
US5858405A (en) *	1996-07-26	1999-01-12	American Home Products Corporation	Oral contraceptive
US5888543A (en) *	1996-07-26	1999-03-30	American Home Products Corporation	Oral contraceptives
US6479475B1 (en)	1996-07-26	2002-11-12	Wyeth	Oral contraceptive
PT956024E (pt) *	1996-07-26	2004-10-29	Wyeth Corp	Metodo contraceptivo oral monofasico e estojo ("kit") compreendendo uma combinacao de uma progestina e estrogenio
US6451778B1 (en)	1996-07-26	2002-09-17	Wyeth	Oral contraceptive
US6765002B2 (en)	2000-03-21	2004-07-20	Gustavo Rodriguez	Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6028064A (en)	1996-09-13	2000-02-22	New Life Pharmaceuticals Inc.	Prevention of ovarian cancer by administration of progestin products
US6034074A (en)	1996-09-13	2000-03-07	New Life Pharmaceuticals Inc.	Prevention of ovarian cancer by administration of a Vitamin D compound
US6511970B1 (en)	1996-09-13	2003-01-28	New Life Pharmaceuticals Inc.	Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
WO2001030355A1 (fr)	1999-10-25	2001-05-03	Laboratoire Theramex	Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
FR2754179B1 (fr)	1996-10-08	1998-12-24	Theramex	Nouvelle composition hormononale et son utilisation
US5898032A (en) *	1997-06-23	1999-04-27	Medical College Of Hampton Roads	Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
PT1007052E (pt) *	1997-08-27	2005-01-31	Ortho Mcneil Pharm Inc	Combinacoes de progestinas de crescimento do endometrico e progestinas de atropia do endometrio com estrogenios, em contracepcao oral
US6787531B1 (en)	1999-08-31	2004-09-07	Schering Ag	Pharmaceutical composition for use as a contraceptive
US20020132801A1 (en) *	2001-01-11	2002-09-19	Schering Aktiengesellschaft	Drospirenone for hormone replacement therapy
FR2832065B1 (fr) *	2001-11-13	2004-11-05	Besins Int Belgique	Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
NZ591627A (en)	2001-12-05	2012-09-28	Teva Womens Health Inc	Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US7772219B2 (en)	2003-05-02	2010-08-10	Teva Women's Health, Inc.	Methods of hormonal treatment utilizing extended cycle contraceptive regimens
CA2771944A1 (en)	2003-07-16	2005-01-27	Teva Women's Health, Inc.	Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
CN1878558A (zh)	2003-11-14	2006-12-13	沃纳奇尔科特公司	梯度雌激素避孕药
EP1535618A1 (en)	2003-11-26	2005-06-01	Schering Aktiengesellschaft	Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
DE102004019743B4 (de)	2004-04-20	2008-11-27	Bayer Schering Pharma Aktiengesellschaft	Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
DE102004026671A1 (de)	2004-05-28	2005-12-15	Grünenthal GmbH	Darreichungsform zur hormonalen Kontrazeption
DE102004026679A1 (de)	2004-05-28	2005-12-15	Grünenthal GmbH	Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026670A1 (de)	2004-05-28	2005-12-15	Grünenthal GmbH	Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
US20070111975A1 (en)	2004-10-07	2007-05-17	Duramed Pharmaceuticals, Inc.	Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
TW200626161A (en)	2004-10-07	2006-08-01	Duramed Pharmaceuticals Inc	Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
UY29527A1 (es) *	2005-05-13	2006-12-29	Schering Ag	Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
US8153616B2 (en)	2005-10-17	2012-04-10	Bayer Pharma Aktiengesellschaft	Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
WO2007076144A2 (en)	2005-12-27	2007-07-05	Duramed Pharmaceuticals, Inc.	Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
US8617597B2 (en)	2006-07-06	2013-12-31	Bayer Intellectual Property Gmbh	Pharmaceutical composition containing a tetrahydrofolic acid
EP1930010A1 (de)	2006-10-20	2008-06-11	Bayer Schering Pharma Aktiengesellschaft	Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
TW200840595A (en) *	2006-12-12	2008-10-16	Organon Nv	Oral contraceptive spray
RU2465907C2 (ru) *	2006-12-20	2012-11-10	Тева Вимен'С Хелс, Инк.	Распадающиеся в полости рта твердые дозированные формы, содержащие прогестин, и способы получения и применение указанных дозированных форм
US20090170823A1 (en)	2007-12-20	2009-07-02	Duramed Pharmaceuticals, Inc.	Dosage Regimens and Pharmaceutical Compositions and Packages for Emergency Contraception
TW200946542A (en) *	2008-03-10	2009-11-16	Vladimir Hanes	New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
EP2343979B1 (en)	2008-10-08	2020-04-08	Agile Therapeutics, Inc.	Transdermal delivery
US9192614B2 (en)	2008-10-08	2015-11-24	Agile Therapeutics, Inc.	Contraceptive transdermal delivery of hormones
WO2010042607A1 (en)	2008-10-08	2010-04-15	Agile Therapeutics, Inc	Transdermal delivery
WO2010111488A1 (en)	2009-03-27	2010-09-30	Agile Therapeutics, Inc.	Transdermal delivery
AU2016264137B2 (en) *	2015-05-18	2021-08-19	Agile Therapeutics, Inc.	Contraceptive compositions and methods for improved efficacy and modulation of side effects
EP3272333A1 (en)	2016-07-22	2018-01-24	Chemo Research, S.L.	Vaginal composition comprising a combination of estrogen and vitamin d

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3669502A (en) †	1971-01-05	1972-06-13	Simpson Timber Co	Pneumatic spreader stoker
US3836651A (en) *	1972-02-22	1974-09-17	Biolog Concepts Inc	Novel oral contraceptive combination
DE2310963A1 (de) †	1972-04-14	1974-09-05	Schering Ag	Methode zur kontrazeption durch verabfolgung von stufenkombinationspraeparaten
DE2365103C3 (de) †	1973-12-21	1980-08-28	Schering Ag, 1000 Berlin Und 4619 Bergkamen	V erwendung von Hormonen zur Kontrazeption
NL8001593A (nl) *	1980-03-18	1981-10-16	Akzo Nv	Meerfasisch combinatiepreparaat voor orale anticonceptie.
US4425339A (en) *	1981-04-09	1984-01-10	Syntex (U.S.A.) Inc.	Treatment of menopausal symptoms
US4826831A (en) *	1983-08-05	1989-05-02	Pre Jay Holdings Limited	Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
US4544554A (en) *	1983-09-26	1985-10-01	Ortho Pharmaceutical Corporation	Triphasic oral contraceptive
DE3347125A1 (de) *	1983-12-22	1985-07-11	Schering AG, 1000 Berlin und 4709 Bergkamen	Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
ZA87332B (en) †	1986-02-27	1987-08-26	Warner Lambert Co	Compositions containing fixed combinations

1987
- 1987-07-08 DK DK198703518A patent/DK174724B1/da not_active IP Right Cessation
- 1987-07-08 IE IE183387A patent/IE61236B1/en active Protection Beyond IP Right Term
- 1987-07-09 ZA ZA875010A patent/ZA875010B/xx unknown
- 1987-07-09 AU AU75379/87A patent/AU597084B2/en not_active Expired
- 1987-07-10 PH PH35524A patent/PH25944A/en unknown
- 1987-07-10 WO PCT/US1987/001646 patent/WO1988000469A1/en not_active Ceased
- 1987-07-10 JP JP62504480A patent/JP2645510B2/ja not_active Expired - Lifetime
- 1987-07-10 KR KR1019880700286A patent/KR960001371B1/ko not_active Expired - Lifetime
- 1987-07-10 PT PT85305A patent/PT85305B/pt unknown
- 1987-07-13 DE DE8787306174T patent/DE3778599D1/de not_active Expired - Lifetime
- 1987-07-13 GB GB8716431A patent/GB2192542B/en not_active Expired - Lifetime
- 1987-07-13 ES ES87306174T patent/ES2033850T5/es not_active Expired - Lifetime
- 1987-07-13 AT AT87306174T patent/ATE75401T1/de active
- 1987-07-13 EP EP87306174A patent/EP0253607B2/en not_active Expired - Lifetime
- 1987-07-14 DK DK365887A patent/DK365887D0/da not_active Application Discontinuation
1992
- 1992-04-30 GR GR920400741T patent/GR3004472T3/el unknown
1993
- 1993-04-29 SG SG55093A patent/SG55093G/en unknown
- 1993-07-15 HK HK673/93A patent/HK67393A/xx not_active IP Right Cessation
1994
- 1994-05-06 CY CY172594A patent/CY1725A/en unknown
2000
- 2000-09-06 LU LU90634C patent/LU90634I2/fr unknown
- 2000-11-03 NL NL300025C patent/NL300025I2/nl unknown

Also Published As

Publication number	Publication date
DK365887D0 (da)	1987-07-14
PT85305A (en)	1987-08-01
JPH01500431A (ja)	1989-02-16
WO1988000469A1 (en)	1988-01-28
ES2033850T5 (es)	2001-07-01
DK351887A (da)	1988-01-16
JP2645510B2 (ja)	1997-08-25
AU597084B2 (en)	1990-05-24
NL300025I2 (nl)	2004-08-02
ES2033850T3 (es)	1993-04-01
PH25944A (en)	1991-12-19
ZA875010B (en)	1989-02-22
KR960001371B1 (ko)	1996-01-26
LU90634I2 (fr)	2000-12-15
DE3778599D1 (de)	1992-06-04
KR880701553A (ko)	1988-11-03
ATE75401T1 (de)	1992-05-15
CY1725A (en)	1994-05-06
GB2192542A (en)	1988-01-20
EP0253607A1 (en)	1988-01-20
GB8716431D0 (en)	1987-08-19
SG55093G (en)	1993-07-09
IE61236B1 (en)	1994-10-19
GR3004472T3 (da)	1993-03-31
DK174724B1 (da)	2003-10-06
AU7537987A (en)	1988-01-21
HK67393A (en)	1993-07-23
EP0253607B1 (en)	1992-04-29
GB2192542B (en)	1990-05-02
NL300025I1 (nl)	2001-01-02
EP0253607B2 (en)	2001-05-23
PT85305B (pt)	1990-03-30
IE871833L (en)	1988-01-15

Legal Events

Date	Code	Title	Description
2004-08-23	CTFF	Application for supplementary protection certificate (spc) filed	Spc suppl protection certif: CA 2003 00026 Filing date: 20031105 Expiry date: 20120708
2007-07-23	PUP	Patent expired
2008-06-16	CTFG	Supplementary protection certificate (spc) issued	Free format text: PRODUCT NAME: GESTODEN, ETHINYLESTRADIOL Spc suppl protection certif: CA 2003 00026 Filing date: 20031105
2012-03-12	CTFL	Supplementary protection certificate (spc) lapsed	Free format text: PRODUCT NAME: GESTODEN, ETHINYLESTRADIOL Spc suppl protection certif: CA 2003 00026 Filing date: 20031105

Publication	Publication Date	Title
DK351887A (da)	1988-01-16	Kombinationsdosisform til hormonbehandling og kontraception for kvinder i praemenopausen
EP0717626B1 (en)	2003-05-28	Preparation for substitution therapy, containing at least one progestogen and at least one extrogen
DK0911029T3 (da)	2002-06-17	Orale antikonceptionsmidler med ultralav dosis, der besidder forlænget aktivitet og fremkalder færre menstruationsblødninger
US3639600A (en)	1972-02-01	Process of establishing cyclicity in a human female
JPH04290828A (ja)	1992-10-15	低エストロゲン経口避妊薬
US3755573A (en)	1973-08-28	Fertility control empoying quinestrol and quingestanol acetate
JP2000502108A (ja)	2000-02-22	ゲストゲンとエストロゲン併用によるほ乳動物の避妊法とキット
NZ333750A (en)	2000-09-29	Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
JP2942560B2 (ja)	1999-08-30	エストロゲン欠乏症治療用組成物
US6642219B1 (en)	2003-11-04	Progestogen-antiprogestogen regimens
WO2000021511A2 (en)	2000-04-20	Subcutaneous medroxyprogesterone acetate for treatment of menopause and endometriosis
Widholm et al.	1974	The use of conjugated oestrogen in oral contraception
Upton	1980	The normal menstrual cycle and oral contraceptives: the physiological basis for a triphasic approach
EP1098653A2 (en)	2001-05-16	Subcutaneous medroxyprogesterone acetate for contraception
Winship	1987	CURRENT VIEWS ON SEX HORMONE REPLACEMENT THERAPY
Olsson	1992	Vaginal rings for contraception: endocrine parameters